ReviewPharmaceutics2024
Nanoscale Prussian Blue and Its Analogues: Design and Applications in Infection Control, Wound Healing and Beyond.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From plant to prosthesis: An engineered biomimetic disc repairs senescence-associated intervertebral disc degeneration in goats.Bioactive materials · 2026Article
- Iron-Hijacking Trojan Horse Nanoplatform Combats Implant-Associated Biofilm Infections Through Immuno-Fibrotic Remodeling.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Colorimetric detection of amino acids enabled by functional nanomaterials: mechanisms, performance evaluation, and translational perspectives.Mikrochimica acta · 2026Review
- Dissolvable Probiotic-Powered Biobatteries: A Safe and Biocompatible Energy Solution for Transient Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Copper Hexacyanoferrates Obtained via FlavocytochromeBiosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prussian blue nanoparticles (PBNPs) have gained significant attraction in the field of nanomedicine due to their excellent biocompatibility, potential for nanoscale production, exceptional photothermal conversion ability, and multi-enzyme mimicking capabilities. PBNPs have made considerable advancements in their application to biomedical fields. This review embarks with a comprehensive understanding of the physicochemical properties and chemical profiling of PB-based nanoparticles, discussing systematic approaches to tune their dimensions, shapes, and sizes, as well as their biomedical properties. Subsequently, the use of PB-based NPs in the biomedical sector is extensively discussed and categorized based on the various features of modified PBNPs, either in combination with drugs or their analogues. Finally, the article highlights the existing challenges associated with current studies and explores the latest developments in these rapidly evolving PB-based nanoplatforms and their therapeutic potentials. Overall, this review aims to deepen the understanding of PB-based NPs and provide crucial insights into their rational design in disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.